FindTrial
Sign In

XALKORI 250 mg hard capsules

DRUG10 trials

Sponsors

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC), Bristol-Myers Squibb Services Unlimited Company, F. Hoffmann-La Roche AG, Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting, Oslo University Hospital HF

Conditions

Advanced solid tumorAnaplastic Large Cell Lymphoma (ALCL)Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)Colorectal cancerInflammatory Myofibroblastic Tumors (IMT)Metastatic non-clear cell renal cell carcinomaMultiple myelomaNeuroblastoma (NBL)

Phase 1

A phase 1B of crizotinib either in combination or as single agent in pediatric patients with ALK, ROS1 or MET positive malignancies
RecruitingCTIS2023-504880-18-00
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Anaplastic Large Cell Lymphoma (ALCL), Inflammatory Myofibroblastic Tumors (IMT), Neuroblastoma (NBL) +2
Start: 2018-04-18Target: 68Updated: 2026-01-21

Phase 2

A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile: The Drug Rediscovery Protocol (DRUP trial)
RecruitingCTIS2023-509152-33-00
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis StichtingAdvanced solid tumor, Multiple myeloma, Non-Hodgkin lymphoma +1
Start: 2016-07-25Target: 3000Updated: 2025-12-19
An open-label single arm interventional phase 2 study to investigate outcome of individualized treatment based on pharmacogenomic profiling and ex vivo drug sensitivity testing of patient-derived organoids in patients with metastatic colorectal cancer
RecruitingCTIS2023-510092-62-00
Oslo University Hospital HFColorectal cancer
Start: 2022-09-27Target: 45Updated: 2025-06-26
Phase 2a non-commercial and non-randomized intervention study evaluating the efficacy of crizotinib in the treatment of children with severe type 2 neurofibromatosis, in particular those excluded from surgery and / or radiotherapy
RecruitingCTIS2024-516607-16-00
Medical University Of WarsawNeurofibromatosis type 2 is a genetically determined primary malignancy resulting from a mutation that disables the function of the cell division control gene and leads to neoplasia such as benign peripheral nervous system tumors and various benign or locally malignant tumors of the central nervous system. Many complications occur in children more often than in adults and significantly shorten the survival period of affected children.
Start: 2024-01-17Target: 1Updated: 2025-05-12
A phase II trial of an individualized treatment strategy for patients with metastatic non-clear cell renal carcinoma
Active, not recruitingCTIS2024-519070-39-00
Region HovedstadenMetastatic non-clear cell renal cell carcinoma
Start: 2020-03-06Target: 30Updated: 2024-10-31

Phase 3

Randomized, Open-label, Multicenter, Phase 3 Trial of Repotrectinib Versus Crizotinib in Participants with Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1 positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
RecruitingCTIS2023-505604-32-00
Bristol-Myers Squibb Services Unlimited CompanyNon small cell lung cancer (NSCLC)
Start: 2024-01-24Target: 83Updated: 2025-09-15
Randomized, Open Label, Multicenter, Phase III Study of Entrectinib Versus Crizotinib in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring ROS1 Gene Rearrangements with and Without Central Nervous System Metastases
RecruitingCTIS2023-507494-18-00
F. Hoffmann-La Roche AGNon-small cell lung cancer with ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) gene rearrangements
Start: 2021-09-24Target: 91Updated: 2026-01-20
Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib In Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
CompletedCTIS2023-506859-13-00
F. Hoffmann-La Roche AGAnaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)
Start: 2014-09-09End: 2025-03-14Target: 51Updated: 2025-04-22
eXALT3: Phase 3 Randomized Study Comparing Ensartinib to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Active, not recruitingCTIS2024-513454-29-00
Xcovery Holding Co. LLCNon-Small Cell Lung Cancer (NSCLC)
Start: 2015-10-15Target: 47Updated: 2025-06-05

Phase 4

A8081075 - CRIZOTINIB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM PFIZER-SPONSORED CRIZOTINIB CLINICAL STUDIES
RecruitingCTIS2024-511128-15-00
Pfizer Inc.This Master Protocol for Crizotinib Continuation Sub-Studies has been designed to provide continued treatment access for eligible participants who continue to derive clinical benefit from study intervention in a Pfizer sponsored crizotinib parent study that will be closed
Start: 2023-01-17Target: 5Updated: 2025-10-27

Related Papers

Checkpoint Blockade Combinations in Tumor Mutational Burden/Load-High Tumors: Insights from the Atezolizumab + Bevacizumab and Nivolumab + Ipilimumab Cohorts in the Drug Rediscovery Protocol.
2025-12-01
Data from Checkpoint Blockade Combinations in Tumor Mutational Burden/Load-High Tumors: Insights from the Atezolizumab + Bevacizumab and Nivolumab + Ipilimumab Cohorts in the Drug Rediscovery Protocol
2025-12-01